Samsung Bioepis Co., Ltd. today released its Second Quarter 2026 Biosimilar Market Report, marking the thirteenth edition of the Quarterly Biosimilar Market Report in the United States (US). The report provides an overview of the market status of all biosimilars available in the US, including approval and launch status, pricing (both Average Sales Price [ASP] and Wholesale Acquisition Cost [WAC]), and market uptake per molecule.
2026 Copyright © News-Matic.com. All Rights Reserved
